A new sema3A derivative as a beneficial therapeutic strategy for immune mediated
Researcher: Zehava Vadasz |Prof. Emeritus Gera Neufeld
Current therapies for systemic lupus erythematosus (SLE), asthma and IBD are only partially effective and more effective therapies are needed, especially in those patients with severe/highly active diseases. Semaphorin3A (sema3A) is well known for its regulatory functions at all stages...